Cover Image

Update breast cancer 2022: Part 4 - Advanced-stage breast cancer = Update Mammakarzinom 2022 : Teil 4 - Brustkrebs in fortgeschrittenen Krankheitsstadien

<p>For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have sho...

Full description

Saved in:
Bibliographic Details
Main Authors: Aktaş, Bahriye (Author) , Fehm, Tanja (Author) , Welslau, Manfred (Author) , Müller, Volkmar (Author) , Lüftner, Diana (Author) , Schütz, Florian (Author) , Fasching, Peter A. (Author) , Janni, Wolfgang (Author) , Thomssen, Christoph (Author) , Witzel, Isabell (Author) , Belleville, Erik (Author) , Untch, Michael (Author) , Thill, Marc (Author) , Tesch, Hans (Author) , Ditsch, Nina (Author) , Lux, Michael P. (Author) , Banys-Paluchowski, Maggie (Author) , Kolberg-Liedtke, Cornelia (Author) , Hartkopf, Andreas (Author) , Wöckel, Achim (Author) , Kolberg, Hans-Christian (Author) , Stickeler, Elmar (Author) , Harbeck, Nadia (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 13. September 2022
In: Geburtshilfe und Frauenheilkunde
Year: 2022, Volume: 82, Issue: 9, Pages: 922-931
ISSN:1438-8804
DOI:10.1055/a-1912-7362
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1055/a-1912-7362
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1912-7362
Get full text
Author Notes:authors: Bahriye Aktas, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A. Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Andreas D. Hartkopf, Achim Wöckel, Hans-Christian Kolberg, Elmar Stickeler, Nadia Harbeck, Andreas Schneeweiss
Description
Summary:<p>For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors - trastuzumab deruxtecan, sacituzumab govitecan and capivasertib - is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.</p>
Item Description:Gesehen am 14.02.2023
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1912-7362

Similar Items